EU Reviews Safety of More Weight-Loss, Diabetes Drugs

Published on July 11, 2023

The European Medicines Agency (EMA) is currently conducting a thorough examination of the safety of weight-loss drug Ozempic and diabetes treatment Saxenda, in response to two cases reporting thoughts of suicide. This review has now been extended to include other medications in the same class. Just like a detective investigating a series of similar crimes, the EMA is taking a closer look at these drugs to determine if there is a potential link between their usage and suicidal thoughts. With the investigation beginning in July, it shows that the EMA places great importance on patient safety and is dedicated to identifying any potential risks or side effects associated with these medications. Safety is of utmost concern when it comes to pharmaceuticals, and understanding these concerns can help improve treatments not just for weight-loss and diabetes, but potentially for other conditions as well. If you’re interested in learning more about this ongoing review and its implications, make sure to check out the full article.

The European Medicines Agency (EMA) said on Tuesday it has extended its probe into Novo Nordisk’s diabetes drug Ozempic and weight-loss treatment Saxenda following two reports of suicidal thoughts to include other drugs in the same class. The agency began its review on July…

Read Full Article (External Site)

Leave a Reply

Your email address will not be published. Required fields are marked *

You may use these HTML tags and attributes:

<a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <s> <strike> <strong>